Speakers and sessions include:
- Recent issues & observations during EU GMP Inspection by Neil Raw – GMP Inspector, MHRA Sustaining a lean QC Microbiology laboratory – case study by Amy McDaniel – Director, QC Microbiology, Pfizer (USA)
- Risk based approach for determining objectionable micro organisms by Dr. Stephen Rawlings – Principal Microbiologist, GlaxoSmithKline
- Regulatory update - items of interest for the microbiologist by Dr Tim Sandle, BPL
- Advances in Microbial Identification by Sarah Wallis – Registered Specialist Biomedical Scientist, Sheffield Teaching Hospitals NHS
- Risk management of contamination during cleanroom operations by Tim Eaton – Sterile Manufacturing Specialist, AstraZeneca
- Sterility Failure – What happens next? by Neil Raw – GMP Inspector, MHRA
- The manufacturing plant microbiologist – breaking barriers and building relationships by Scott Smith – Microbiology QC Leader, Sanofi-Aventis
- Best practices for performing contamination investigations by David Keen – Supply Microbiology Manager, Reckitt Benckiser
- How to justify doing less monitoring, sampling and testing and still pass an inspection by Stewart Green – Managing Director, GXP Consulting
- Developing a meaningful environmental monitoring programme for sterile/non sterile products by Dr Julia Mottishaw – QP, Teva Runcorn
- Applications of risk assessment in the microbiology laboratory by Amy McDaniel, Pfizer
- Cleaning and Disinfectant Validation by Kim Morwood, MGS
- What is an objectionable organism? by Stephen Rawling, GlaxoSmithKline
- Method Validation by Julia Mottishaw, Teva Runcorn
To read more read the brochure: Pharmig Conference
No comments:
Post a Comment